GILEAD SCIENCES INC (GIS.DE) Stock Price, Forecast & Analysis
FRA:GIS • US3755581036
GIS.DE Key Statistics, Chart & Performance
The current stock price of GIS.DE is 125.3 EUR. In the past month the price increased by 10.12%. In the past year, price increased by 17.28%.
GIS.DE Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to GIS.DE. When comparing the yearly performance of all stocks, GIS.DE is one of the better performing stocks in the market, outperforming 79.01% of all stocks.
GIS.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GIS.DE. GIS.DE has an excellent profitability rating, but there are some minor concerns on its financial health.
GIS.DE Financial Highlights
Over the last trailing twelve months GIS.DE reported a non-GAAP Earnings per Share(EPS) of 6.92. The EPS increased by 76.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 27.88% | ||
| ROA | 13.86% | ||
| ROE | 37.8% | ||
| Debt/Equity | 0 |
GIS.DE Forecast & Estimates
37 analysts have analysed GIS.DE and the average price target is 120.14 EUR. This implies a price decrease of -4.12% is expected in the next year compared to the current price of 125.3.
For the next year, analysts expect an EPS growth of 9.44% and a revenue growth 3.45% for GIS.DE
GIS.DE Ownership
GIS.DE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.69 | 43.591B | ||
| ARGX | ARGENX SE | 27.81 | 43.541B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.326B | ||
| ABVX | ABIVAX SA | N/A | 8.714B | ||
| 2X1 | ABIVAX SA | N/A | 8.698B | ||
| GXE | GALAPAGOS NV | N/A | 1.885B | ||
| GLPG | GALAPAGOS NV | N/A | 1.871B | ||
| IVA | INVENTIVA SA | N/A | 1.166B | ||
| 6IV | INVENTIVA SA | N/A | 1.112B | ||
| NANO | NANOBIOTIX | N/A | 1.031B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About GIS.DE
Company Profile
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
Company Info
GILEAD SCIENCES INC
333 Lakeside Dr
Foster City CALIFORNIA US
Employees: 17600
Phone: 13026587581
GILEAD SCIENCES INC / GIS.DE FAQ
What does GIS do?
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company is headquartered in Foster City, California and currently employs 17,600 full-time employees. The company is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. The company is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. The company also develops the HB-400 program and the HB-500 program. The company develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. The company has a cancer program, namely TREX1. The company operates in more than 35 countries worldwide.
What is the stock price of GILEAD SCIENCES INC today?
The current stock price of GIS.DE is 125.3 EUR. The price decreased by -1.37% in the last trading session.
Does GILEAD SCIENCES INC pay dividends?
GILEAD SCIENCES INC (GIS.DE) has a dividend yield of 2.16%. The yearly dividend amount is currently 2.65.
How is the ChartMill rating for GILEAD SCIENCES INC?
GIS.DE has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about GILEAD SCIENCES INC (GIS.DE) stock?
37 analysts have analysed GIS.DE and the average price target is 120.14 EUR. This implies a price decrease of -4.12% is expected in the next year compared to the current price of 125.3.
Would investing in GILEAD SCIENCES INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GIS.DE.
What is the employee count for GIS stock?
GILEAD SCIENCES INC (GIS.DE) currently has 17600 employees.